KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Finished Goods (2019 - 2025)

Opko Health (OPK) has disclosed Finished Goods for 4 consecutive years, with $44.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods rose 36.16% year-over-year to $44.0 million, compared with a TTM value of $44.0 million through Dec 2025, up 36.16%, and an annual FY2025 reading of $44.0 million, up 36.16% over the prior year.
  • Finished Goods was $44.0 million for Q4 2025 at Opko Health, up from $42.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $44.0 million in Q4 2025 and bottomed at $32.3 million in Q4 2024.
  • Average Finished Goods over 4 years is $37.3 million, with a median of $36.0 million recorded in 2023.
  • The sharpest move saw Finished Goods decreased 9.2% in 2024, then skyrocketed 36.16% in 2025.
  • Year by year, Finished Goods stood at $37.1 million in 2022, then dropped by 4.19% to $35.6 million in 2023, then fell by 9.2% to $32.3 million in 2024, then surged by 36.16% to $44.0 million in 2025.
  • Business Quant data shows Finished Goods for OPK at $44.0 million in Q4 2025, $42.3 million in Q3 2025, and $42.2 million in Q2 2025.